Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prothena (DE:0PT)
FRANKFURT:0PT
Prothena (0PT) Stock Price & Analysis
1 Followers
0PT Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€18.70 - €71.00
Previous Close€19.3
Volume0.00
Average Volume (3M)111.00
Market Cap
€1.05B
Enterprise Value€431.00M
Total Cash (Recent Filing)$670.90M
Total Debt (Recent Filing)$10.73M
Price to Earnings (P/E)N/A
Beta0.11
Next Earnings
May 07, 2024EPS Estimate
-€1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,720,455
10 Day Avg. Volume0
30 Day Avg. Volume111
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.00
Price to Sales (P/S)19.23
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.06
Enterprise Value/Gross Profit8.00
Enterprise Value/Ebitda-12.65
Forecast
1Y Price Target
€66.85Price Target Upside246.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Prothena News
PremiumCompany Announcements
Prothena Appoints Daniel G. Welch as New Board Chair
Bulls Say, Bears Say
Bulls Say
Drug EfficacyRecent data indicates prasinezumab may slow motor function impairment in Parkinson's Disease, suggesting a potential improvement in patient outcomes.
Regulatory ConfidenceStrong alignment with FDA on trial design for birtamimab, indicating potential approval readiness and increasing the likelihood of market entry.
Trial DesignThe primary endpoint for the Padova trial is based on clinically meaningful measures for Parkinson's Disease, enhancing the credibility of the trial results.
Bears Say
Analyst SentimentDowngrade to Neutral from Buy with a new $38 price objective, as clarity on the clinical profile for PRX012 in Alzheimer's disease is needed.
Corporate TransparencyThe stock has been under pressure following unexpected change of disclosure strategy and lack of granular timing for the next updates.
Drug EfficacyTrontinemab also saw a high ADA rate, with 75% of the high dose cohort having infusion-related reaction.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.24% Other Institutional Investors
99.76% Public Companies and
Individual Investors
0PT FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was €18.70 and its highest was €71.00 in the past 12 months.
What is Prothena’s market cap?
Currently, no data Available
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is May 07, 2024 which is in 9 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Feb 15, 2024. The company reported -€1.177 earnings per share for the quarter, missing the consensus estimate of -€1.098 by -€0.078.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -€1.08.
How many shares outstanding does Prothena have?
Currently, no data Available
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -€1.177 in its last earnings report, missing expectations of -€1.098. Following the earnings report the stock price went down -1.515%.
Which hedge fund is a major shareholder of Prothena?
Among the largest hedge funds holding Prothena’s share is Maple Rock Capital Partners Inc.. It holds Prothena’s shares valued at 14M.
---
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€66.85 (246.37% Upside)
€66.85 (246.37% Upside)
Blogger Sentiment
Bullish
DE:0PT Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.86%
12-Months-Change
Fundamentals
Return on Equity
-24.85%
Trailing 12-Months
Asset Growth
-8.13%
Trailing 12-Months
Company Description
Prothena
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
---
0PT Company Deck
---
0PT Earnings Call
Q4 2024
0:00 / 0:00
---
0PT Stock 12 Months Forecast
Average Price Target
€66.85
▲(246.37% Upside)
Technical Analysis
Best Analysts Covering 0PT
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+2.00%
reiterated a buy rating 10 months ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +2.00% per trade.
---